Skip to main content
Premium Trial:

Request an Annual Quote

Manhattan Labs to Offer CombiMatrix Miscarriage Array Tests to New York Clients

NEW YORK (GenomeWeb News) – Manhattan Labs will market CombiMatrix's chromosomal microarray testing services to customers in the New York City metropolitan area, the firms said today.

Manhattan Labs CEO Ken Cerney said in a statement that the independent clinical laboratory opted to offer the test as part of a new focus on miscarriage management, and added that his firm "believes in the growing importance and clinical advantages microarray testing provides for appropriate patients."

The deal follows a New York State Department of Health decision in June to allow Irvine, Calif.-based CombiMatrix to provide on a conditional basis array-based miscarriage testing on samples from within the state.

CombiMatrix CEO Mark McDonough said in a statement that adding Manhattan Labs' marketing and distribution support to its own internal sales efforts will be "very beneficial to our growth and prosperity."

In Tuesday morning trade on the Nasdaq, shares of CombiMatrix were up 6 percent at $3.23.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more